相关实验视频

Updated: Jan 11, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

新型机器学习模型在代谢功能障碍相关的型肝炎与纤维化时优于非侵入性测试

Konstantinos Stefanakis¹, Geltrude Mingrone², Jacob George³

¹Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

|November 9, 2025

概括

新型机器学习模型显著提高了检测代谢功能障碍相关的脂肪肝炎 (MASH) 纤维化阶段F2到F3和肝硬化. 这些先进的工具解决了新兴MASH疗法的关键诊断缺口.

科学领域:

肝病学和胃肠病学肝病学和胃肠学
生物标志物发现发现
医学成像和诊断医学成像和诊断

背景情况:

非侵入性测试 (NIT) 缺乏系统评估,以检测代谢功能障碍相关的纤维化阶段F2-F3的脂肪肝炎 (MASH),这是新兴治疗的关键组.
目前的诊断差距阻碍了MASH疗法和临床试验的患者鉴定.
肝硬化 (F4) 检测也需要优化的非侵入性方法.

研究的目的:

评估现有和新型的非侵入性试验 (NIT) 检测MASH与纤维化阶段F2-F3.
评估NIT在排除肝硬化 (F4) 的表现.
开发和验证机器学习 (ML) 模型,以改进MASH纤维化检测.

主要方法:

分析了905名活检验证个体的队列,包括健康对照.
评估了28个基于生物标志物,成像或算法的NIT,用于MASH纤维化阶段F2-F4.
通过分类梯度增强开发并验证了使用常规变量和激素标记器的机器学习模型.

主要成果:

现有的NIT在F2-F3检测方面表现不佳 (FAST AUC为0.67).
新的ML模型实现了F2-F3检测的AUC高达0.86,精度提高 (87%) 和积极的预测值 (65%).
对于肝硬化 (F4),ML模型的平均AUC为0.93,高于AGILE4+等常规工具的平均AUC.

结论:

与现有的NIT相比,新型ML模型显著提高了MASH F2-F3和肝硬化的检测.
这些ML工具解决了FDA定义的MASH治疗窗口的关键诊断缺口.
开发的模型显示了MASH临床试验和治疗入学患者选择的前景.

关键词:

马什F2-F3F2-F3 马什F2-F3 马什F2-F3 马什F2-F3 马斯尔德马斯尔德是什么意思非侵入性测试是一种非侵入性测试.在Resmetirom中使用Resmetirom.

更多相关视频

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

相关概念视频

Ultrasound II: Endoscopic Ultrasound and FibroScan

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...